Role of calpains in diabetes mellitus: A mini review

Molecular and Cellular Biochemistry

Volumn 261, Issue 1, 2004, Pages 161-167

  Harris, Fredrick ^a   Chatfield, Lee ^a   Singh, Jaipaul ^a   Phoenix, David A ^a  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

Calcium; Calpains; Diabetes mellitus; Gene; Glucose; Pancreas

Indexed keywords

CALPAIN; GLUCOSE; INSULIN; MESSENGER RNA; MUTANT PROTEIN;

CELLULAR DISTRIBUTION; DIABETES MELLITUS; DISEASE PREDISPOSITION; GENE MAPPING; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GLUCONEOGENESIS; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; MOLECULAR CLONING; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREDICTION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN POLYMORPHISM; PROTEIN STRUCTURE; SHORT SURVEY; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

CALPAIN; DIABETES MELLITUS, TYPE 2; HUMANS; LINKAGE (GENETICS); PROTEIN STRUCTURE, TERTIARY;

MAMMALIA;

EID: 3442893855     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:MCBI.0000028751.10560.dc     Document Type: Short Survey

References (88)

1. Redondo MJ, Eisenbarth GS: Genetic control of autoimmunity in Type I diabetes and associated disorders. Diabetologia 45: 605-622, 2002
2. Harris MI: Definition and classification of diabetes mellitus. In: D. LeRoith, SI. Taylor, J.M. Olefsk (eds). Diabetes mellitus: A fundamental and clinical text. Lippincott, Williams and Wilkins, Philadelphia, 2000, pp 326-335
3. Busch CP, Hegele RA: Genetic determinants of type 2 diabetes mellitus. Clin Genet 60: 243-254, 2001
4. Metzger BE, Coustan DR: Summary and recommendations of the Fourth International Workshop: Conference on gestational diabetes mellitus. The organizing committee. Diabetes Care 21: B161-B167, 1998
5. Gloyn AL: The search for type 2 diabetes genes. Ageing Res Rev 2: 111-127. 2003
6. Owen K, Hattersley AT: Maturity-onset diabetes of the young: From clinical description to molecular genetic characterization. Baillires Best Pract Res Clin Endocrinol Metab 15: 309-323, 2001
7. Steiner DF, Tager HS, Namjo K, Chan SJ, Rubenstein JH. Familial syndromes of hyperproinsulinemia with mild diabetes. In: C.R. Scriver, A.L. Beadet, W.S. Sly, D. Valle (eds). The metabolic and molecular basis of inherited disease. McGraw Hill, New York, 1995, pp 897-904
8. Taylor SI: Diabetes mellitus. In: C.R. Scriver, A.L. Beadet, W.S. Sly, D. Valle (eds). The metabolic and molecular basis of inherited disease. McGraw Hill, New York, 1995, pp 843-896
9. Nishigori H, Yamada S, Kohama T, Tomura H, Sho K, Horikawa Y, Bell GI, Takeuch T, Takeda J: Frameshift mutation, A263fsinsGG, in the hepatocyte nuclear factor-1 beta gene associated with diabetes and renal dysfunction. Diabetes 47: 1354-1355, 1998
10. Stoffers DA, Ferrer J, Clarke WL, Habener JF: Early-onset type-II mellitus (MODY4) linked to IPF1. Nat Genet 17: 138-139, 1997
11. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF: Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 15: 106-110, 1997
12. Malecki MT, Jhal US, Antonellis A, Fields L, Doria A, Orban T, Saad M, Warram JH, Montminy M, Krolewski AS: Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nat Genet 23: 323-328, 1999
13. Adorini I, Gregori S, Harrison LC: Understanding autoimmune diabetes: Insights from mouse models. Trends Mol Med 8: 31-38, 2002
14. Bach JF: Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 15: 516-542, 1994
15. Castano L, Eisenbarth GS: Type-I diabetes: A chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol 8: 647-679, 1990
16. Herr M, Dudbridge F, Zavattari P, Cucca F, Guja C, March R, Campbell RD, Barnett AH, Bain SC, Todd JA, Koeleman BP: Evaluation of fine mapping strategies for a multifactorial disease locus: Systematic linkage and association analysis of IDDM1 in the HLA region on chromosome 6p21. Hum Mol Genet 9: 1291-1301, 2000
17. Concannon P, Gogolin-Ewens KJ, Hinds DA, Wapelhorst B, Morrison VA, Stirling B, Mitra M, Farmer J, Williams SR, Cox NJ, Bell GI, Risch N, Spielman RS: A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus. Nat Genet 19: 292-296, 1998
18. Amos AF, McCarty DJ, Zimmer P: The rising global burden of type 2 diabetes and its complications: Estimates and projections to the year 2000. Diabetic Med 14: S7-S85, 1997
19. Arner P: The adipocyte in insulin resistance: Key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 14: 137-145, 2003
20. Petersen KF, Shulman GI: Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol 90: 11G-18G, 2002
21. Bailey CJ: Potential new treatments for type 2 diabetes. Trends Pharmacol Sci 21: 259-265, 2000
22. Bailey CJ: Insulin resistance and antidiabetic drugs. Biochem Pharmacol 58: 1511-1520, 1999
23. Sacks DB, McDonald JM: The pathogenesis of type II diabetes mellitus: A polygenic disease. Am J Clin Pathol 105: 149-156, 1996
24. Scheen AJ, Luyckx FH: Obesity and liver disease. Best Pract Res Clin Endocrinol Metab 16: 703-716, 2002
25. Balen A, Rajkowha M: Polycystic ovary syndrome? - a systemic disorder? Best Pract Res Clin Obstet Gynaecol 17: 263-274, 2003
26. Naoumovaa RP, Betteridge DJ: A new drug target for treatment of dyslipidaemia associated with type 2 diabetes and the metabolic syndrome? Lancet 359: 2215-2216, 2002
27. Conlin PR: Efficacy and safety of angiotensin receptor blockers: A review of losartan in essential hypertension. Curr Ther Res 62: 79-91, 2001
28. Plutzky J, Viberti G, Haffner S: Atherosclerosis in type 2 diabetes mellitus and insulin resistance: Mechanistic links and therapeutic targets. J Diabetes Complications 16: 401-415, 2002
29. Raza JA, Movahed A: Current concepts of cardiovascular diseases in diabetes mellitus. Int J Cardiol 89: 123-134, 2003
30. Zanella M-T, Ribeiro AB: The role of angiotensin II antagonism in type 2 diabetes mellitus: A review of renoprotection studies. Clin Ther 24: 1019-1034, 2002
31. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW: The Penn State Retina Research Group: Diabetic retinopathy: More than meets the eye. Surv Ophthalmol 47: S253-S262, 2002
32. Coppini DV, Bowtell PA, Weng C, Young PJ, Sonksen PH: Showing neuropathy is related to increased mortality in diabetic patients - a survival analysis using an accelerated failure time model. J Clin Epidemiol 53: 519-523, 2000
33. Goll DE, Thompson VF, Li HQ, Wei W, Cong JY: The calpain system. Physiol Rev 83: 731-801, 2003
34. Perrin BJ, Huttenlocher A: Calpain. Int J Biochem Cell Biol 34: 722-725, 2002
35. Strobl S, Fernandez-Catalan C, Braun M, Huber R, Masumoto H, Nakagawa K, Irie A, Sorimachi H, Bourenkow G, Bartunik H, Suzuki K, Bode W: The crystal structure of calcium-free human m-calpain suggests an electrostatic switch mechanism for activation by calcium. Proc Natl Acad Sci USA 97: 588-592, 2000
36. 2+ dependent protease activity and a novel mode of enzyme activation. EMBO J 18: 6880-6889, 1999
37. Reverter D, Braun M, Fernandez-Catalan C, Strobl S, Sorimachi H, Bode W: Flexibility analysis and structure comparison of two crystal forms of calcium- free human m-calpain. J Biol Chem 383: 1415-1422, 2002
38. Reverter D, Sorimachi H, Bode W: The structure of calcium-free human m-calpain: Implications for calcium activation and function. Trends Cardiovasc Med 11: 222-229, 2001
39. Reverter D, Strobl S, Fernandez-Catalan C, Sorimachi H, Suzuki K, Bode W: Structural basis for possible calcium-induced activation mechanisms of calpains. Biol Chem 382: 753-766, 2001
40. Farkas A, Tompa P, Friedrich P: Revisiting ubiquity and tissue specificity of human calpains. Biol Chem 384: 945-949, 2003
41. Huang YH, Wang KKW: The calpain family and human disease. Trends Mol Med 7: 355-362, 2001
42. Sorimachi H, Suzuki K: The structure of calpain. J Biochem 129: 653-664, 2001
43. Carafoli E, Molinari M: Calpain: A protease in search of a function? Biochem Biophys Res Conmun 247: 193-203, 1998
44. Sato K, Kawashima S: Calpain function in the modulation of signal transduction molecules. Biol Chem 382: 743-751, 2001
45. Yajima Y, Kawashima S: Calpain function in the differentiation of mesenchymal stem cells. Biol Chem 383: 757-764, 2002
46. Rami A: Ischemic neuronal death in the rat hippocampus: The calpain-calpastatin-caspase hypothesis. Neurobiol Dis 13: 75-88, 2003
47. Yamashima T: Implication of cysteine proteases calpain, cathepsin and caspase in ischemic neuronal death of primates. Prog Neurobiol 62: 273-295, 2000
48. Sazontova TG, Matskevich AA, Arkhipenko YV: Pathophysiology review article calpains: Physiol Pathophysiol Signif 6: 91-102, 1999
49. Gordon ES, Hoffman EP: The ABC's of limb-girdle muscular dystrophy: Alpha-sarcoglycanopathy, Bethlem myopathy, calpainopathy and more. Curr Opin Neurol 14: 567-573, 2001
50. Richard I, Roudaut C, Saenz A, Pogue R, Grimbergen JEMA, Anderson LVB, Beley C, Cobo AM, de Diego C, Eymard B, Gallano P, Ginjaar HB, Lasa A, Pollitt C, Topaloglu H, Urtizberea JA, de Visser M, van der Kooi A, Bushby K, Bakker E, de Munain AL, Fardeau M, Beckmann JS: Calpainopathy - a survey of mutations and polymorphisms. Am J Hum Genet 64: 1524-1540, 1999
51. Vanderklish PW, Bahr BA: The pathogenic activation of calpain: A marker and mediator of cellular toxicity and disease states. Int J Exp Path 81: 323-339, 2000
52. Nixon RA: A "protease activation cascade" in the pathogenesis of Alzheimer's disease. Ann NY Acad Sci 924: 117-131, 2000
53. Azuma M, Fukiage C, David LL, Shearer TR: Activation of calpain in lens: A Review and proposed mechanism. Exp Eye Res 64: 29-538, 1997
54. Horikawa Y, Oda N, Cox NJ, Li XQ, Orho-Melander M, Hara M, Hinokio Y, Lindner TH, Mashima H, Schwarz PEH, del Bosque-Plata L, Horikawa Y, Oda Y, Yoshiuchi I, Colilla S, Polonsky KS, Wei S, Concannon P, Iwasaki N, Schulze T, Baier LJ, Bogardus C, Groop L, Boerwinkle E, Hanis CL, Bell GI: Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2: 163-175, 2000
55. Hanis CL, Boerwinkle E, Chakraborty R, Ellsworth DL, Concannon P, Stirling B, Morrison VA, Wapelhorst B, Spielman RS, GogolinEwens KJ, Shephard JM, Williams SR, Risch N, Hinds D, Iwasaki N, Ogata M, Omori Y, Petzold C, Rietzsch H, Schroder HE, Schulze J, Cox NJ, Menzel S, Boriraj VV, Chen X, Lim LR, Lindner T, Mereu LE, Wang YQ, Xiang K, Yamagata K, Yang Y, Bell GI: A genome-wide search for human non-insulin dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet 13: 161-166, 1996
56. Cox NJ, Frigge M, Nicolae DL, Concannon P, Hanis CL, Bell GI, Kong A: Loci on chromosomes 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican Americans. Nat Genet 21: 213-215, 1999
57. Lynn S, Evans JC, White C, Frayling TM, Hattersley AT, Tumbull DM, Horikawa Y, Cox NJ, Bell GI, Walker M: Variation in the calpain-10 gene affects blood glucose levels in the British population. Diabetes 51: 247-250, 2002
58. Garant MJ, Kao WHL, Brancati F, Coresh J, Rami TM, Hanis CL, Boerwinkle E, Shuldiner AR: SNP43 of CAPN1O and the risk of type 2 diabetes in African-Americans - the atherosclerosis risk in communities study. Diabetes 51: 231-237, 2002
59. Tsai HJ, Sun GY, Weeks DE, Kaushal R, Wolujewicz M, McGarvey ST, Tufa J, Viali S, Deka R: Type 2 diabetes and three Calpain-10 gene polymorphisms in Samoans: No evidence of association. Am J Hum Genet 69: 1236-1244, 2001
60. Hegele RA, Harris SB, Zinman B, Hanley AJG, Cao H: Absence of association of type 2 diabetes with CAPN1O and PC-1 polymorphisms in Oji-Cree. Diabetes Care 24: 1498-1499, 2001
61. Elbein SC, Chu W, Ren QF, Hemphill C, Schay J, Cox NJ, Hanis CL, Hasstedt SJ: Role of calpain-10 gene variants in familial type 2 diabetes in Caucasians. J Clin Enodocr Metab 87: 650-654, 2002
62. Daimon M, Oizumi T, Saitoh T, Kameda W, Yamaguchi H, Ohnuma H, Igarashi M, Manaka H, Kato T: Calpain 10 gene polymorphisms are related, not to type 2 diabetes, but to increased serum cholesterol in Japanese. Diabetes Res Clin Prac 56: 147-152, 2002
63. Evans JC, Frayling TM, Cassell PG, Saker PJ, Hitman GA, Walker M, Levy JC, O'Rahilly S, Rao PVS, Bennett AJ, Jones EC, Menzel S, Prestwich P, Simecek N, Wishart M, Dhillon R, Fletcher C, Millward A, Demaine A, Wilkin T, Horikawa Y, Cox NJ, Bell GI, Ellard S, McCarthy MI, Hattersley AT: Studies of association between the gene for calpain-10 and type 2 diabetes mellitus in the United Kingdom. Am J Hum Genet 69: 544-552, 2001
64. Malecki MT, Moczulski DK, Klupa T, Wanic K, Cyganek K, Frey J, Sieradzki J: Homozygous combination of calpain 10 gene haplotypes is associated with type 2 diabetes mellitus in a Polish population. Eur J Endocrinol 146: 695-699, 2002
65. Cassell PG, Jackson AE, North BV, Evans JC, Syndercombe-Court D, Phillips C, Ramachandran A, Snehalatha C, Gelding SV, Vijayaravaghan S, Curtis D, Hitman GA: Haplotype combinations of calpain 10 gene polymorphisms associate with increased risk of impaired glucose tolerance and type 2 diabetes in South Indians. Diabetes 51: 1622-1628, 2002
66. Rasmussen SK, Urhammer SA, Berglund L, Jensen JN, Hansen L, Echwald SM, Borch-Johnsen K, Horikawa Y, Mashima H, Lithell H, Cox NJ, Hansen T, Bell GI, Pedersen O: Variants within the calpain-10 gene on chromosome 2q37 (NIDDM1) and relationships to type 2 diabetes, insulin, and impaired acute insulin secretion among Scandinavian Caucasians. Diabetes 51: 3561-3567, 2002
67. Horikawa Y, Oda N, Yu L, Imamura S, Fujiwara K, Makino M, Seino Y, Itoh M, Takeda J: Genetic variations in calpain-10 gene are not a major factor in the occurrence of type 2 diabetes in Japanese. J Clin Endocr Metab 88: 244-247, 2003
68. Hoffstedt J, Naslund E, Arner P: Calpain-10 gene polymorphism is associated with Reduced β3-Adrenoceptor function in human fat cells. J Clin Endocr Metab 87: 3362-3367, 2002
69. Gonzalez A, Abril E, Roca A, Aragon MJ, Figueroa MJ, Velarde P, Royo JL, Real LM, Ruiz A: CAPN10 alleles are associated with polycystic ovary syndrome. J Clin Endocrinol Metab 87: 3971-3976, 2002
70. Sugimoto K, Katsuya T, Ishikawa K, Iwashima Y, Yamamoto K, Fu Y, Matsuo A, Motone M, Rakugi H, Ogihara T: UCSNP-43 G/A polymorphism of calpain-10 gene is associated with hypertension and dyslipidemia in Japanese population. Am J Hypertens 16: A82, 2003
71. Cox NJ: Challenges in identifying genetic variation affecting susceptibility to type 2 diabetes: Examples from studies on the calpain 10 gene. Hum Mol Gen 10: 2301-2305, 2001
72. Baier LJ, Permana PA, Yang XL, Pratley RE, Hanson RL, Shen GQ, Mott D, Knowler WC, Cox NJ, Horikawa Y, Oda N, Bell GI, Bogardus C: A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J Clin Invest 106: R69-R73, 2000
73. Yang XL, Pratley RE, Baier LJ, Horikawa Y, Bell GI, Bogardus C, Permana PA: Reduced skeletal muscle calpain-10 transcript level is due to a cumulative decrease in major isoforms. Mol Genet Metabol 73: 111-113, 2001
74. Ma H, Fukiage C, Kim YH, Duncan MK, Reed NA, Shih M, Azuma M, Shearer TR: Characterization and expression of calpain 10 - a novel ubiquitous calpain with nuclear localization. J Biol Chem 276: 28525-28531, 2001
75. Uitterlinden AG, Burger H, Huang O, Yue F, McGuigan FEA, Grant SFA, Hofman A, van Leeuwen JTPM, Pols HAP, Ralston SH: Relation of alleles of the collagen type I 1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N Engl J Med 338: 1016-1021, 1998
76. Sun L, Cox NJ, McPeek MS: A statistical method for identification of polymorphisms that explain a linkage result. Am Hum Genet 70: 399-411, 2002
77. Braun C, Enge M, Theisinger B, Welter C, Seifert M: CAPN 8: Isolation of a new mouse calpain-isoenzyme. Biochem Biophys Res Commun 260: 671-675, 1999
78. Bell GI, Polonsky KS: Diabetes melittus and genetically programmed defects in beta-cell function. Nature 414: 788-791, 2001
79. Orho-Melander M, Klannemark M, Svensson MK, Ridderstrale M, Lindgren CM, Groop L: Variants in the calpain-10 gene predispose to insulin resistance and elevated free fatty acid levels. Diabetes 51: 2658-2664, 2002
80. Stumvoll M, Wahl HG, Machicao F, Haring H: Insulin sensitivity of glucose disposal and lipolysis: No influence of common genetic variants in IRS-1 and CAPN1O. Diabetologia 45: 651-656, 2002
81. Hoffstedt J, Ryden M, Lofgren P, Orho-Melander M, Groop L, Arner P: Polymorphism in the Calpain 10 gene influences glucose metabolism in human fat cells. Diabetologia 45: 276-282, 2002
82. Patel YM, Lane MD: Role of calpain in adipocyte differentiation. Proc Natl Acad Sci 96: 1279-1284, 1999
83. Smith LK, Rice MR, Garner WG: The insulin-induced down regulation of IRS-1 in 3T3-L1 adipocytes is mediated by a calcium dependent thiol protease. Mol Cell Endocrinol 122: 81-92, 1996
84. Zhang H, Hoff H, Sell C: Downregulation of IRS-1 protein in thapsigargin-treated human prostate epithelial cells. Exp Cell Res 289: 352-358, 2003
85. Sreenan SK, Zhou YP, Otani K, Hansen PA, Currie KPM, Pan CY, Lee JP, Ostrega DM, Pugh W, Horikawa Y, Cox NJ, Hanis CL, Burant CF, Fox AP, Bell GI, Polonsky KS: Calpains play a role in insulin secretion and action. Diabetes 50: 2013-2020, 2001
86. Schulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 106: 171-176, 2000
87. Zhou YP, Sreenan S, Pan CY, Currie KPM, Bindokas VP, Horikawa Y, Lee JP, Ostrega D, Ahmed N, Baldwin AC, Cox NJ, Fox AP, Miller RJ, Bell GI, Polonsky KS: A 48-hour exposure of pancreatic islets to calpain inhibitors impairs mitochondrial fuel metabolism and the exocytosis of insulin. Metab Clin Exp 52: 528-534, 2003
88. Walder K, McMillan J, Lapsys N, Kriketos A, Trevaskis J, Civitarese A, Southon A, Zimmet P, Collier G: Calpain 3 gene expression in skeletal muscle is associated with body fat content and measures of insulin resistance. Int J Obesity 26: 442-449, 2002